Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

NCT02625935 · clinicaltrials.gov ↗

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Sponsor

NanoString Technologies, Inc.